Candidiasis Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Candidiasis

September 2018 | 65 pages | ID: CC1B2974FCCEN
VPAResearch

Abstracts

Candidiasis Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Candidiasis Infection pipeline products.

DISEASE OVERVIEW

Candidiasis infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as ‘lockjaw’ as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

REPORT DESCRIPTION

The Candidiasis Infection pipeline guide presents complete overview of drugs currently being developed for Candidiasis Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Candidiasis Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Candidiasis Infection pipeline candidates is included.

Major companies participating in therapeutic development of Candidiasis Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Candidiasis Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Candidiasis Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Candidiasis Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF CANDIDIASIS INFECTION PIPELINE REPORT INCLUDES

• Panorama of Candidiasis Infection pipeline markets including statistics on therapeutic drugs and companies involved
• Candidiasis Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
• Candidiasis Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
• Overview of companies participating in Candidiasis Infection pipeline with short introduction to their businesses and pipeline projects
• For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
• Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Candidiasis Infection pipeline therapeutics

REASONS TO BUY

• Get clear understanding of the entire Candidiasis Infection pipeline, with details on active projects
• Get in detail information of each product with updated information on each project along with key milestones
• Know the list of companies participating in global Candidiasis Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

Contents

I. KEY FINDINGS

1. Companies Investing in Candidiasis Infection Pipeline include
  Number of Companies with Candidiasis Infection projects in pre-clinical Development
  Number of Companies with Candidiasis Infection projects in Clinical Development
  Candidiasis Infection Pipeline Companies based in Americas
  Candidiasis Infection Pipeline Companies based in Europe
  Candidiasis Infection Pipeline Companies based in Asia Pacific
  Candidiasis Infection Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  Candidiasis Infection Pipeline Agents in Pre- clinical/Discovery stage of Development
  Candidiasis Infection Pipeline Agents in Clinical Development stage
  Candidiasis Infection Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the Candidiasis Infection Pipeline agents

II. INSIGHTS INTO CANDIDIASIS INFECTION PIPELINE

1. Disease Overview
  Introduction to Candidiasis Infection
  Symptoms and Causes of Candidiasis Infection
  Treatment or Prevention Options for Candidiasis Infection
  Other Details
2. Phase wise Pipeline Compounds
  Candidiasis Infection Pipeline Pre- Clinical/Discovery stage Drugs
  Candidiasis Infection Pipeline Phase 1 stage Drugs
  Candidiasis Infection Pipeline Phase 2 stage Drugs
  Candidiasis Infection Pipeline Phase 3 stage Drugs
  Candidiasis Infection Pipeline Pre-Registration stage Drugs
3. Company wise Candidiasis Infection Pipeline Compounds
4. Candidiasis Infection Pipeline by Mechanism of Action

III. CANDIDIASIS INFECTION PIPELINE COMPOUND DETAILS

Amphotericin B
APX-001
APX-001A
AC17
Isavuconazonium
Anti fungal drug
candidiasis therapeutics
BSG005
CLX-1593
JSM-11
Rezafungin
P-113 for Oral Candidiasis
microbiome(Dermala)
Arasertaconazole
Drug for Candidiasis
pHyph
P113
ABV3
iCo-009
MAT2203
TP enzyme for Candidiasis
NM147
NOSO-F2
NP339
NDV-3
NDV-3A
Orynotides
ProF-001
Occidiofungin
SCY-078
SLP0901
Voriconazole sodium phosphate
Myc-102
TOL-463
VT-1161
VIS-FNG
candidiasis vaccine
Drug Details
  1. Snapshot
    Name of the Therapeutic Agent
     Originator
    Developing Company
    Co-Developer/License Partner
    Orphan Drug/Fast Track/Designation
    Development Phase
  2. Drug Overview
  3. Mechanism of Action
  4. Current Status
  5. Clinical Trial Details

IV. CANDIDIASIS INFECTION PIPELINE COMPANY BRIEFS

Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Amplyx Pharmaceuticals Inc
Arietis Corp
Basilea Pharmaceutica
Biomar Microbial Technologies
Bionex Pharmaceuticals LLC
Biosergen AS
Cellix Bio Pvt Ltd
Chelation Partners Inc
Cidara Therapeutics Inc
Demegen
Dermala Inc
Ferrer Internacional, SA
Fox Chase Chemical Diversity Center Inc
Gedea Biotech AB
General Biologicals Corp
Hennepin Life Sciences LLC
iCo Therapeutics Inc.
Matinas BioPharma
Metabolab Inc
Nanomerics Ltd
Nosopharm SAS
Novabiotics Ltd
NovaDigm Therapeutics Inc
NovaDigm Therapeutics Inc
Oryn Therapeutics
Profem GmbH
Sano Chemicals Inc
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
TGV Laboratories Inc
Toltec Pharmaceuticals LLC
Viamet Pharmaceuticals Inc
Visterra Inc
Wellstat Vaccines LLC

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL CANDIDIASIS INFECTION PIPELINE MARKET

VI. APPENDIX

1. Publisher’s Expertise
2. Research Methodology
3. Contact Information
Some of the sections depicted above may be removed or modified on the basis of information availability